DocuSign Stock Gets A Lift From Earnings Beat And AI Contract Tools

• DocuSign reported Q2 2026 sales of US$875.75 million and net income of US$77.72 million, raised full year revenue guidance, and detailed broader access to its Iris powered Model Context Protocol Server across major AI agents and enterprise platforms.
• By making its agreement intelligence callable directly from tools like Slack, Salesforce, Gemini, and BearingPoint's GenAIQ, DocuSign is pushing contract workflows deeper into everyday enterprise systems and AI agents where commercial decisions already happen.
• The focus now is on how DocuSign's MCP rollout across leading AI agents may influence the broader investment narrative around agreement intelligence.

Activate your research edge by scanning the 72 profitable AI stocks that aren't just burning cash already aligning real-world workflows with AI agents, in the same way DocuSign is pushing agreement intelligence into everyday tools.

DocuSign Investment Narrative Recap

To own DocuSign, you need to believe the business can turn its eSignature base into a broader agreement platform, while managing slower headline growth. The latest quarter showed US$875.75 million in sales, US$77.72 million in net income, and higher full year revenue guidance, which points to some operational momentum. The near term hinge is clear. Execution on intelligent agreement management and AI agents needs to offset maturing eSignature demand. The biggest immediate risk sits in that same transition if IAM uptake, pricing, or international traction do not keep pace with expectations.

The September 30 general availability of DocuSign's Model Context Protocol Server for agents like Claude, ChatGPT, Gemini, and Copilot looks tightly linked to that catalyst. Putting Iris powered agreement intelligence directly into AI agents and tools such as Slack and Salesforce makes IAM usage more frequent and embedded in daily workflows. That creates a cleaner read on whether customers actually rely on DocuSign for governed contract actions, not just signatures. It also brings sharper execution risk. Reliability, governance controls, and perceived value need to hold up as usage spreads across more enterprise surfaces.

Yet against this backdrop of AI momentum and raised guidance, one pressure point still sits uncomfortably in the background...

Read the full DocuSign narrative to see the case behind these numbers.

DocuSign's current analyst storyline points to US$4.0b in revenue and US$482.3m in earnings by 2029. That path assumes 7.5% yearly revenue growth and an earnings increase of about US$173m from US$309.1m today.

DocuSign's forecasts put fair value at $60.16 versus the $68.41 share price, representing a 12% downside to its current price that keeps pressure on the premium.

Exploring Other Perspectives

One alternate view puts competitive risk front and center. The most bearish analysts worried that commoditised e-signature tools could cap DocuSign's progress and were only modeling revenue of about US$3.8b and earnings near US$517.6m by 2029. Those forecasts came before this MCP news, so you may see those opinions shift as agent based usage becomes clearer.

If you want broader pricing context for DocuSign, compare this fair value view with the 7 other fair value estimates for DocuSign.

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own analysis and judgment.

• A great starting point for your DocuSign research is our analysis highlighting 3 key rewards that could impact your investment decision.
• See our latest analysis for DocuSign. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate DocuSign's overall financial health at a glance.

Looking For More Ideas Beyond DocuSign?

If you want to stress test your thesis on DocuSign, it can help to line it up next to other opportunities that fit different return and risk profiles. The Simply Wall St Screener lets you scan the market through that lens, then compare businesses on the same footing.

• If you want to focus on quality at a discount, line up companies using the 49 high quality undervalued stocks and see which ones deserve deeper work.
• If capital protection is front of mind, start with the 83 resilient stocks with low risk scores and weigh those businesses against DocuSign on volatility and balance sheet strength.
• If you are hunting for under-followed opportunities, cast a wider net with the 17 high quality undiscovered gems and build a watchlist that matches your own return targets.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com